Symptomatic Carotid Arteries: Early or Late Emergency Revascularization?

Carotid endarterectomy continues to be the safest technique for emergency revascularization. However, 48 hours after index event, different strategy outcomes will become comparable. 

Carótidas sintomáticas: ¿revascularización urgente, precoz o retardada?

Multiple advances in device development have brought promising results for carotid revascularization patients with symptomatic stenosis. Regardless these developments, optimal revascularization timing after index event remains unclear

This study included patients with symptomatic carotid stenosis undergoing transcarotid artery revascularization (TCAR), transfemoral carotid stenting (TFCAS), or carotid endarterectomy (CEA) at different times after index event. 

Procedures were regarded as urgent (0 to 2 days after last event), early (3 to 14 days) or late (15 to 180 days).

Primary end point was inhospital death or stroke. Secondary end point added transient ischemic event. 

The study included 18,643 symptomatic revascularizations: 10.8% were urgent, 39.8% were early, and the remaining half was late.


Read also:  TICO: Age Impacts the Effect of Antiplatelet Monotherapy.


Patients undergoing TFCAS showed the highest rate of stroke and death at all timing cohorts. 

Among urgent cases, CAE had 4% events vs 6.9% for TFCAS and 6.5% for TCAR (p=0.018). These differences tended to level off the later patients were treated. 

When adjusting for risk, OR resulted similar between patients undergoing CAE and TCAR. 

Conclusion

CAE continues to be the safest revascularization approach for emergency cases. TCAR and CAE seem similar after 48 hours. 

Original Title: In-Hospital Outcomes of Urgent, Early, or Late Revascularization for Symptomatic Carotid Artery Stenosis.

Reference: Christina L. Cui et al. J Am Heart Assoc. 2021 Dec 21;10(24):e022700. doi: 10.1161/JAHA.121.022700.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....